Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Slipping Diet Market Reduces GNC Full-Year Sales

This article was originally published in The Tan Sheet

Executive Summary

Continued decreases in the diet category were offset by gains in other product groups, resulting in a 2% decline in GNC's 2005 consolidated revenues, the company reported during a fourth-quarter and year-end earnings call March 2

You may also be interested in...



GNC

Domestic comparable corporate store sales increased 8.1% for the fourth quarter, but decreased 1.5% for the full year, the supplement retailer announces Jan. 12. For franchise stores, sales increased 1.5% in the fourth quarter and decreased 4.8% for the full year. The company's comparable store sales "improved each successive quarter in 2005, finishing the year signficantly ahead of first quarter results," GNC states, attributing lower sales in early 2005 to "negative trends in the diet category." The firm is "very pleased with our progress in rebuilding our business in 2004"...

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099161

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel